Dissecting trait neurobiological abnormalities in bipolar disorder (BD) from those characterizing episodes of mood disturbance will help elucidate the aetiopathogenesis of the illness. This selective review highlights the immunological, neuroendocrinological, molecular biological and neuroimaging abnormalities characteristic of BD, with a focus on those likely to reflect trait abnormalities by virtue of their presence in euthymic patients or in unaffected relatives of patients at high genetic liability for illness. Trait neurobiological abnormalities of BD include heightened pro-inflammatory function and hypothalamic-pituitary-adrenal axis dysfunction. Dysfunction in the intracellular signal transduction pathway is indicated by elevated protein kinase A activity and altered intracellular calcium signalling. Consistent neuroimaging abnormalities include the presence of ventricular enlargement and white matter abnormalities in patients with BD, which may represent intermediate phenotypes of illness. In addition, spectroscopy studies indicate reduced prefrontal cerebral N-acetylaspartate and phosphomonoester concentrations. Functional neuroimaging studies of euthymic patients implicate inherently impaired neural networks subserving emotional regulation, including anterior limbic, ventral and dorsal prefrontal regions. Despite heterogeneous samples and conflicting findings pervading the literature, there is accumulating evidence for the existence of neurobiological trait abnormalities in BD at various scales of investigation. The aetiopathogenesis of BD will be better elucidated by future clinical research studies, which investigate larger and more homogenous samples and employ a longitudinal design to dissect neurobiological abnormalities that are underlying traits of the illness from those related to episodes of mood exacerbation or pharmacological treatment.
Introduction
Bipolar disorder (BD) is an illness of high heritability characterized by recurrent episodes of elation and depression, with interspersed periods of relatively normal mood. There has been a wide array of research studies into neurobiological abnormalities associated with BD in recent years incorporating diverse levels of scale and investigative techniques from intracellular signalling processes through to neuroimaging of neural networks. These have revealed marked heterogeneity of many neurobiological abnormalities described to date. This is most likely contributed to by the varying mood state of patients when assessed, the use of cross-sectional study designs and the examination of relatively small samples of patients. In an effort to distil out those neurobiological abnormalities, which are likely to be underlying trait features of the disorder, some research groups have specifically examined samples of patients during euthymia or remission. An allied research design that seeks to identify those trait abnormalities related to underlying susceptibility genes for the illness (that is, intermediate phenotypes) is to assess unaffected individuals genetically liable for BD, such as firstdegree relatives of patients or co-twins. Any such abnormalities cannot be because of the effects of medication or illness course, which might contribute to neurobiological abnormalities identified in euthymic patients. Identifying intermediate phenotypes could assist in elucidating the pathways from genotypic variation to the clinical syndrome of BD. 1 Alternatively, the identification of neurobiological abnormalities, which vary with mood state, best identified through longitudinal study designs, may help clarify the pathophysiology of affective episodes and serve as markers to assess the impact of therapeutic interventions.
This selective review provides an overview of the neurobiological trait abnormalities characteristic of BD in the fields of immunology, neuroendocrinology, molecular biology and neuroimaging. The review focuses on research that has sought to identify the fundamental trait-related abnormalities as indicated by their detection in adult patients with confirmed euthymia, across all phases of the illness or in unaffected genetically liable subjects. The neuropsychological abnormalities persisting through euthymic BD or characteristic of those at genetic risk are reviewed in detail elsewhere. [2] [3] [4] [5] Immunology and neuroendocrinology
The immune and neuroendocrine systems enable successful recovery from infectious or inflammatory processes by recognizing and eliminating foreign antigens, regulating inflammatory processes, coordinating tissue repair and remodelling, and ensuring that the altered metabolic demands of the host are adequately met. 6 Cytokines and related secretory products from immune cells communicate with the endocrine and central nervous system to modulate their collective functions. 7 
Cytokines
Cytokines are large polypeptide mediators that regulate growth, differentiation and function of many cell types. 8 Cytokines can be classed as proinflammatory, such as interleukin-1 (IL-1), IL-6, IL-8 and tumour necrosis factor, or anti-inflammatory, such as IL-2, IL-4, IL-10 and IL-13. 9 Cytokines have been implicated in depressive disorder through the manifestation of profound depressive symptoms in patients receiving interferon treatment, 10 activation of the inflammatory response in depression, 11, 12 identification of potent negative immunoregulatory effects of antidepressants 13 and findings of abnormal cutaneous glucocorticoid receptor function in antidepressant-resistant patients. 14 A number of studies have assessed the extent to which cytokine function differs from control samples in the differing mood phases of BD. Trait-related heightened pro-inflammatory function in BD is supported by evidence for increased numbers of circulating activated T cells and soluble IL-2 receptors in a cross-sectional controlled study of bipolar patients across all phases of the illness, which persisted at 2-year longitudinal follow-up. 15 There are also reports of increased cell-mediated immunity activation in manic bipolar patients that persist into remission 16 and increased production of the same pro-inflammatory cytokines (IL-8 and tumour necrosis factor-a) in both manic and depressed bipolar patients. 17 Increased pro-inflammatory (IL-6 and tumour necrosis factor-a) and reduced anti-inflammatory (IL-4) cytokine levels have been reported in unmedicated manic patients compared with healthy controls, with some normalization of pro-inflammatory function longitudinally after mood-stabilizing treatment, 18 indicating partial reversal of the proinflammatory state. Lithium therapy appears to reduce the number of cytokine-secreting cells, further supporting the anti-inflammatory potential of mood stabilizers. 19 Heightened pro-inflammatory function is not specific to BD and has also been identified in patients with schizophrenia and with major depressive disorders when compared with healthy controls, 20 with normalization post-neuroleptic treatment. 21 In summary, there is evidence for trait-based proinflammatory processes operating in BD by virtue of increased pro-inflammatory cytokine production across all phases of illness including remission, although acute exacerbation appears to be associated with an accentuation of this pro-inflammatory state and successful treatment with a partial reversal.
Hypothalamic-pituitary-adrenal axis
Dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis in mood disorders is evident from hypersecretion of cortisol in unipolar depression 22 and from the failure of depressed patients to suppress secretion of cortisol with the dexamethasone suppression test. 23 The more sensitive combined dexamethasone suppression test and Corticotrophin-Releasing Hormone (CRH) challenge test (DEX/CRH) 24 has enabled superior detection of impaired central glucocorticoid receptor signalling in patients with depression and BD compared with their healthy counterparts, 25 findings that have been replicated to a lesser extent across a broad range of psychiatric illnesses. HPA axis dysfunction in affective disorders may well arise from decreased function or expression of brain glucocorticoid receptors, resulting in glucocorticoid resistance and subsequent elevation of circulating cortisol as a compensatory mechanism. 26 Healthy first-degree relatives of depressed patients also display impaired glucocorticoid receptor signalling after DEX/CRH administration, suggesting that glucocorticoid dysfunction may be a familial trait marker for affective disorder. 27 Evidence for trait-related HPA axis dysfunction in BD using the combined DEX/CRH test is shown by the consistently enhanced cortisol response in patients with acute mania or bipolar depression when compared with controls that persist on a longitudinal follow-up of up to 6 months' remission. [28] [29] [30] Interestingly, glucocorticoid receptor dysfunction, as measured by the dexamethasone suppression test, correlates with declarative and working memory deficits in euthymic BD patients, suggesting that trait-related glucocorticoid receptor dysfunction may be aetiologically linked to the cognitive dysfunction frequently reported even in remitted BD. 31 Combined immunological and endocrinological investigations have also revealed the presence of Tcell steroid resistance as a potential trait marker in BD. 32 Similar findings in major depressive disorder, 33 and schizophrenia, 34, 35 suggest that such HPA axis dysfunction may represent a trait marker across the broader affective and psychotic disorder spectrum.
In summary, the well-recognized HPA axis dysfunction and associated glucocorticoid resistance, which characterizes unipolar depression, is likely to reflect a trait-related abnormality in BD, given its presence across different phases of the illness, including remission. This may reflect the action of susceptibility genes for the illness, as it has been reported in genetically liable unaffected subjects who have first-degree relatives with depression and with BD.
Molecular biology
Intracellular signal transduction pathways in the central nervous system are uniquely responsible for coordinating the cellular response to information impinging on the cell from multiple sources and time frames. There has been considerable interest in the role that some of these pathways and their individual components may play in the pathogenesis of BD, including the cyclic adenosine monophosphate (cAMP)-generating pathway, the role of G-proteins, the phosphoinositide pathway, intracellular calcium signalling and the subsequent regulation of gene expression by these pathways.
cAMP, PKA and BDNF The cAMP-generating pathway, as outlined in Figure 1 , is activated by the binding of a neurotransmitter to the G-protein-coupled transmembrane receptor, inducing a conformational change in the G-protein, stimulation of adenyl cyclase and ultimately the conversion of adenosine triphosphate to cAMP. cAMP regulates many cellular functions, including metabolism and gene transcription, through the activation of protein kinase A (PKA). Activated PKA phosphorylates other protein substrates, including cAMP-response element-binding protein (CREB), a transcription factor that provides a critical link between signal transduction and the expression of potentially relevant target genes, including the neuroprotective brain-derived neurotrophic factor (BDNF). 36 There is a body of evidence linking unipolar depression with reduced serum BDNF levels, which normalize with antidepressant treatment. [37] [38] [39] Both unmedicated euthymic and depressed bipolar patients have significantly higher cAMP-stimulated PKA activity than controls. 40 Furthermore, whereas depressed or manic patients with BD show increased levels of the PKA catalytic subunit compared with euthymic patients or controls, all bipolar patients, regardless of mood phase, have increased levels of Rap1 (a protein substrate of PKA that has a role in regulating cell adhesion) compared with controls. 41 Euthymic bipolar patients are reported to have increased PKA activity and reduced cAMP binding compared with controls, but without any corresponding difference in BDNF levels. 42 Measurement of cAMP signalling system activity during PKA activation/inhibition in euthymic bipolar patients revealed increased basal PKA activity, increased PKA catalytic subunit levels and increased pCREB expression in bipolar patients compared with controls. 43 However, inhibition of PKA resulted in decreased downstream BDNF expression specifically in the bipolar group, which implies an underlying trait-related defect in BDNF expression with compensatory upregulation of cAMP signalling to normalize BDNF levels in BD. There are conflicting results regarding serum BDNF levels in euthymic BD, with reduced serum BDNF levels reported, 44 but other studies showing staterelated BDNF abnormalities in BD. 45, 46 A comparative study of patients with BD or chronic schizophrenia showed elevated BDNF levels in chronic schizophrenia compared with euthymic BD or healthy controls, interpreted by the authors as reflecting the impact of medication or lengthy course of schizophrenic illness. 47 A longitudinal 1-year follow-up of patients with first-episode schizophrenia or BD showed lowered BDNF levels, which progressively increased to healthy control level at 1-year follow-up, 48 which supports the hypothesis that abnormal BDNF levels are state related in affective and psychotic disorders.
Thus, there is some evidence to suggest increased PKA activity as a trait feature of BD, with preliminary support for trait-related increased Rap1 levels. Although BDNF levels vary with episodes of illness and their treatment, it remains unclear whether some persistent BDNF reduction represents a BD trait. including unmedicated bipolar depression, 49 unmedicated mania 50 and lithium-treated euthymic bipolar patients, 50 ,51 suggesting a trait-related G-protein subunit abnormality in BD, although state-related abnormalities have also been reported. [52] [53] [54] There is also evidence that increased receptor-G-protein coupling in unmedicated manic bipolar patients normalizes subsequent to lithium or valproic acid therapy. 55 This disagreement in the literature is most likely fuelled by heterogeneous samples and differing methods of G-protein quantification, including different G-protein subunits and measurement in leukocytes or platelets. The weight of current evidence suggests that G-protein abnormalities in BD are state related, with limited longitudinal data suggesting normalization of levels following treatment with mood stabilizers.
G-proteins

Phosphoinositide pathway
Activation of the phosphoinositide second messenger system by neurotransmitter/G-protein binding results in activated phospholipase C, hydrolysis of phosphatidylinositol 4,5-bisphosphate and creation of second messengers, such as 1,2-diacylglycerol and inositol 1,4,5-triphosphate (IP 3 ). 1,2-Diacylglycerol activates the PKC system, whereas IP 3 stimulates calcium release from smooth endoplasmic reticulum. 56 Cross-sectional studies of platelet membrane phospholipids imply state-related abnormalities in phosphatidylinositol 4,5-bisphosphate levels and PKC activity in BD compared with controls. [57] [58] [59] Euthymic bipolar patients taking lithium do display reduced phosphatidylinositol 4,5-bisphosphate levels compared with controls; 60, 61 however, this is most likely through mechanisms of inositol depletion 62 and inositol monophosphatase inhibition by lithium. 63 
Intracellular calcium signalling
In addition to their role in synaptic transmission and neurotransmitter release, calcium ions are involved in the mediation of more diverse cellular events, including synaptic plasticity, cell survival, exocytosis and cell death. Intracellular calcium signalling and homoeostasis are regulated in a complex manner that includes extracellular entry, release from intracellular stores, specific uptake into organelles and binding to particular proteins. 64 Elevated basal calcium concentrations have been detected in transformed B lymphoblasts in bipolar I disorder compared with those in bipolar II disorder, major depression or healthy controls, 65 associated with abnormalities in receptor-coupled and G-protein-coupled adenylyl cyclase activity. 66, 67 Increased total serum and ionized calcium has been reported in euthymic lithium-treated patients compared with healthy controls. 68 Increased free intracellular calcium ion concentrations have been reported in both depression and mania. 69 Lower basal intracellular calcium values have also been shown in the olfactory receptor neurons of euthymic bipolar patients compared with healthy controls. 70 Thus, calcium homoeostasis appears altered across all mood states in BD.
Mechanisms for this are hypothesized to include abnormalities in store-operated calcium channels, endoplasmic reticulum and mitochondria. 71 Interestingly, post-mortem research has identified significantly decreased levels of mRNA coding for mitochondrial proteins and reduced expression of genes regulating oxidative phosphorylation and proteosome degradation in the hippocampus of BD patients compared with schizophrenia or controls. 72 
Neuroimaging
Several neuroimaging studies have attempted to identify neuroanatomical, neurochemical or neurophysiological abnormalities associated with BD, although heterogeneity of patient samples has resulted in considerable inconsistencies in the literature. One might expect neuroanatomical abnormalities in particular to vary little across different clinical phases of illness; however, limited longitudinal data exist to confirm this assertion.
Structural neuroimaging
Most published structural neuroimaging studies of adult BD have been performed on heterogeneous samples of patients with respect to mood state, familial subtype, illness subtype, medication status, co-morbid alcohol/substance abuse and magnetic resonance imaging (MRI) analysis.
Region-of-interest studies have largely focused either upon global tissue volumes or upon measurements of limbic or prefrontal structures because of the apparent involvement of these regions in mood regulation. Early computerized tomography imaging studies of bipolar patients indicated that the disorder was associated with enlarged ventricle-to-brain ratio, albeit to a lesser extent than that found in schizophrenia. 73, 74 Region-of-interest studies using MRI have largely confirmed, including by metaanalysis, 75, 76 that BD is associated with enlargement of the lateral ventricles.
In contrast to schizophrenia and major depression, no overall difference has been found in whole-brain volume or in hippocampal volume between BD patients, in any phase of the illness, and controls. 75, [77] [78] [79] [80] [81] Studies that have examined amygdala volume have produced particularly conflicting findings, with some reporting amygdala enlargement in BD, [82] [83] [84] [85] whereas others report amygdala volume reduction. [86] [87] [88] There is some evidence for reduced volume of specific prefrontal subregions in BD. 89 Significant interest has been focused upon the subgenual prefrontal cortex because of its key role in mood regulation, but again results are conflicting with studies reporting reduced volume of this structure, 90, 91 and no difference. 92, 93 Studies using exploratory automated MRI analysis techniques, such as voxel-based morphometry, have equally produced variable findings. A range of regional grey matter deficits has been reported, involving the thalamus, 94 99 thalamus, 100 anterior cingulate 98, 101 and prefrontal cortices. 98 Other computational morphometry studies report no grey matter abnormalities. 102, 103 Interestingly, there is accumulating evidence that lithium and other mood-stabilizing medications may increase grey matter volume, 76, 104, 105 possibly through neurotrophic effects. Specific increases in grey matter volume following lithium treatment in bipolar patients have been reported in the hippocampus, [106] [107] [108] [109] bilateral cingulate and paralimbic cortices, 101 and medial temporal lobe. 110 Prefrontal grey matter increase has also been reported in lithium-treated healthy volunteers. 111 Preliminary neuroimaging findings also suggest a neurotrophic effect for valproate and quetiapine. 112 Thus, variable structural MRI results from studies incorporating remitted patients may be related to differential use of mood-stabilizing agents.
One of the most consistent structural MRI abnormalities reported in BD is that of increased rates of deep white matter hyperintensities, qualitatively rated from T 2 -weighted or FLAIR sequence MRI scans. 113, 114 These are found with normal ageing and in association with vascular disease, but have been consistently reported at higher frequency in BD, even in young patients. 115 A more detailed analysis of deep white matter changes in BD has been facilitated by application of diffusion tensor imaging, which can be used to detect microstructural abnormalities in myelinated tracts. Diffusion tensor imaging studies have largely reported disturbance of white matter microstructure in BD, particularly affecting the prefrontal regions. [116] [117] [118] [119] [120] Findings from MRI studies of clinically screened euthymic BD patients include significantly reduced cortical grey matter, reduced cerebral white matter and increased ventricular and sulcal CSF compared with matched controls, 121 and reduced temporal lobe volumes bilaterally. 122 Assessment of white matter integrity between the subgenual cingulate and the amygdalo-hippocampal complex in euthymic bipolar patients revealed an increased number of reconstructed white matter fibres in this tract on the left side compared with that in controls, interpreted by the authors as consistent with lateralized ventrallimbic system dysregulation in BD. 123 In addition to the apparently variable effects of medication on regional brain structure, abnormalities detected during euthymia may be related to chronicity effects after several episodes of illness or other confounds of having the illness, such as alcohol/ substance abuse. MRI studies that include unaffected relatives of bipolar patients may assist the identification of bipolar endophenotypic traits by avoiding the confounding effects of illness-related factors on brain structure. Such studies have reported a high prevalence of deep white matter hyperintensities in unaffected relatives of patients with BD from densely affected families, 124 decreased left hemispheric white matter in unaffected co-twins from twin pairs discordant for BD 125 and reduced anterior thalamic grey matter in unaffected relatives of patients with BD. 94 McDonald et al. 126 reported grey matter deficits in the right anterior cingulate and ventral striatum, and distributed white matter deficits in bilateral frontal, left temporoparietal, right parietal regions and anterior corpus callosum in association with increasing genetic liability for BD in a sample of multiply affected BD families.
In summary, there is extensive heterogeneity among structural imaging studies of BD. The most consistent findings are of ventricular enlargement and increased rates of deep white matter hyperintensities, as outlined in Table 1 . Structural abnormalities in prefrontal and limbic regions are regularly reported but lack consistency to date, most likely contributed to by heterogeneous clinical samples and the varying effects of mood-stabilizing medications on brain structure. Studies focused upon clinically confirmed euthymic individuals have detected grey and white matter deficits. Considerable evidence is accumulating for trait-related white matter abnormalities in the disorder, which may also reflect genetic liability as they are found early in the course of illness and in genetically liable unaffected relatives of patients with BD.
Magnetic resonance spectroscopy
Magnetic resonance spectroscopy (MRS) is a useful technique for investigating the activity of neurochemical compounds in regions of the brain. The most commonly used technique involves the use of proton ( 1 H) MRS to measure the concentration of N-acetylaspartate (NAA), creatine and phosphocreatine (Cr þ PCr), choline-containing compounds (Cho) and myo-inositol (Ino). Phosphorus ( 31 P) MRS has also been used to assess aspects of cellular metabolism.
Proton MRS
Several proton MRS studies have been completed using small numbers of patients in varying mood states, 127 with reports of reduced cerebral NAA in the dorsolateral prefrontal cortex, anterior cingulate and hippocampal regions, potentially indicative of neuronal cell loss 127 or mitochondrial dysfunction. 128 Several of these studies were performed on predominantly euthymic patients 127 and therefore indicate trait-related abnormalities in NAA, which appears prominent in the hippocampal region. 129 NAA levels may be increased or normalized by lithium treatment, 130, 131 with valproate and quetiapine also reported to modulate NAA/choline ratios. 136 Significantly elevated concentrations of choline, suggestive of impaired phospholipid metabolism and breakdown, are reported especially in the basal ganglia of depressed and euthymic BD patients, irrespective of mood state 132 or lithium treatment, 133 although reduced frontal choline in a sample of unmedicated bipolar patients in varying mood states has also been reported. 153 There has been little consistency in the results of studies to date examining other neurochemicals with proton MRS. Interestingly, in a recent study of 21 stable remitted patients with BD taking lithium, patients were found to have increased hippocampal glutamate, which correlated strongly with NAA concentrations. 134 There was also a negative correlation between hippocampal glutamate and diurnal cortisol, and the authors suggest that the high glutamate levels may be related to chronic lithium maintenance, which acts to protect the hippocampus from adverse effects of stress and glucocorticoids. 134 Phosphorus MRS Increased levels of phosphomonoesters (PMEs) imply an increased rate of membrane phospholipid turnover, whereas decreased PME levels indicate a stalling of membrane synthesis. Interestingly, PME appears to be increased in both the depressed and manic phases of BD, 135 but reduced in frontal and temporal regions during the euthymic phase compared with healthy controls. 137, 138, 154 Lower PME levels in euthymia are supported by a meta-analysis of phosphorus MRS findings in BD, 155 supporting PME elevation as a state-related abnormality linked to mood episode and PME reduction as a traitrelated abnormality reflecting membrane synthesis inhibition.
In summary, there are many inconsistencies in the MRS data to date, but most evidence supports a traitrelated reduction of NAA and PME, especially in prefrontal or hippocampal subregions, and increased choline in the basal ganglia. These neurochemical abnormalities are likely to reflect neuronal loss and membrane abnormalities underlying the disorder in these regions and may be normalized by moodstabilizing treatments. [113] [114] [115] [116] [117] [118] [119] [120] 122, 123, 125, 126 þ þ Volumetric abnormalities of amygdala [82] [83] [84] [85] [86] [87] [88] þ /À Temporo-parietal and cortical grey matter deficits 95, 98, 99, 102, 103, 121 þ /À Reduced volume of subgenual prefrontal cortex [90] [91] [92] [93] 95, 96, 98, [101] [102] [103] þ /À Volumetric abnormalities of thalamus 75, 94, 100, 102, 103, 122 þ /À Enlargement of basal ganglia 85 þ /À MRS Reduced hippocampal and cerebral NAA 127, 129 þ þ Raised choline levels 132, 133 þ Reduced PME levels 137, 154, 155 þ
Functional neuroimaging
Reduced orbitofrontal and ventral prefrontal cortex activity 139, 142, 143 þ Altered dorsal anterior cingulate activity 139, 140, 159 þ /À Impaired DLPFC activation 158 þ /À Increased activation of anterior limbic regions, temporal and parietal cortices and cingulate during cognitive or affective tasks 144, [148] [149] [150] [161] [162] [163] [164] [165] [166] þ /À Abbreviations: BDNF, brain-derived neurotrophic factor; MRS, magnetic resonance spectroscopy; NAA, N-acetylaspartate; PKA, protein kinase A; PME, phosphomonoester. þ þ : Strong evidence to support finding as a trait marker; þ : evidence to support finding as a trait marker; þ /À: some evidence in support of finding as a trait marker.
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Functional neuroimaging
PET studies PET has been used to study regional brain activity by the measurement of glucose metabolism and regional cerebral blood flow at rest or during completion of cognitive tasks. State-related alterations in prefrontal activation during mood exacerbation is shown by significantly reduced blood flow and glucose metabolism in the subgenual prefrontal cortex in unmedicated bipolar patients in the depressed phase compared with healthy controls, 90 whereas patients in the manic phase have increased blood flow in the left dorsal anterior cingulate cortex and left head of caudate when compared with euthymic patients. 156 Other evidences showed that manic patients display reduced activity in right-sided prefrontal cortex during cognitive testing and reduced activity bilaterally in the orbitofrontal cortex at rest, when compared with either euthymic patients or healthy controls. 157 These findings suggest reduced control of prefrontal executive function in the manic state, which concurs with the clinical presentation of such patients.
Impaired learning of new verbal information has been associated with failure to activate the left dorsolateral prefrontal cortex in euthymic bipolar patients, suggesting that trait-related impaired dorsolateral prefrontal cortex functioning may underlie the well-recognized memory deficits that persist into euthymia. 158 Reduced orbitofrontal cortex and increased dorsal anterior cingulate activity were shown both in euthymic patients and in their unaffected siblings during a task designed to introduce transient sadness, indicating a trait abnormality in this network. 139 Bipolar patients also had reduced activity in the medial frontal cortex, whereas their siblings had increased activity in this area, suggesting a potential protective/resilience effect in siblings. 139 The same authors had reported earlier that euthymic patients display reduced activity in the dorsal anterior cingulate on emotional challenge. 140 SPECT studies A small SPECT study of regional cerebral perfusion in euthymic BD identified reduced blood flow in distributed regions, with the greatest hypoperfusion present in the cingulate region. 159 SPECT has also been applied to the investigation of receptor function in BD, with one study finding no evidence of altered striatal dopamine binding in response to amphetamine challenge in a sample of euthymic BD patients compared with healthy controls. 160 fMRI studies fMRI has been used to assess relative changes in regional cerebral blood flow in response to cognitive or affective tasks in BD patients in various clinical phases. Depressed bipolar patients tend to have decreased prefrontal activation and manic patients tend to have decreased prefrontal activation and increased anterior cingulate activation. Other anterior limbic areas also display increased activation, including the striatum, thalamus and amygdala during manic or depressive state. These findings are consistent with a model in which impaired prefrontal (cognitive) modulation of anterior limbic (emotional) networks underlies mood exacerbation in BD. 141, 161 Several fMRI studies of confirmed euthymic samples of patients with BD have been published in recent years, which have investigated regional haemodynamic activity during the stimulation of cognitive and/or affective neural networks.
Cognitive tasks
Examination of cerebral activity in response to a colour-naming Stroop task in patients during different phases of bipolar illness revealed state-related prefrontal activation, in addition to left rostral ventral prefrontal cortex region attenuation in all patient groups, including euthymic patients, compared with controls, which indicates an enduring trait vulnerability. 142 While performing a counting Stroop interference task, euthymic bipolar patients displayed reduced activation of the ventrolateral prefrontal region, temporal regions, midline cerebellum and putamen, suggesting failure to activate secondary brain regions involved in the prevention of impulsive responses. 143 Strakowski et al. 161 also identified increased activation of anterior limbic regions and corresponding abnormal activation of the visual association cortex during an attentional task in unmedicated euthymic bipolar patients compared with controls, despite similar performance on the task. Adler et al. 144 performed a two-back working memory task with euthymic bipolar patients and matched controls. After controlling for poorer performance among patients, bipolar subjects still showed greater activation of the fronto-polar prefrontal cortex, temporal cortex, posterior parietal cortex and thalamus, suggesting activation of alternative neural networks in patients to complete this working memory task. Using a similar working memory task in a sample of lithiumtreated euthymic bipolar 1 patients, Monks et al. 162 reported increased activation in right medial frontal, left precentral and left supramarginal regions and reduced activation in bilateral frontal, temporal and parietal regions compared with controls, interpreted as failure to engage fronto-temporal executive function as a core trait of BD. An fMRI study of a language processing task in a similar sample reported increased activity in euthymic patients within frontal and cerebellar/fusiform/lingual regions, areas known to have a role in executive function and language generation. 163 An event-related working memory experiment of euthymic bipolar patients identified attenuated prefrontal activity across three conditions of working memory load, further supporting dysfunctional fronto-cortico-limbic networks during execu-tive processing as a trait feature of BD. 150 A recent working memory fMRI study of remitted patients with BD from multiply affected families and their unaffected first-degree relatives showed that unaffected relatives displayed increased activity in the left ventrolateral prefrontal region while performing the task compared with controls, supportive of increased activity in this region as a potential endophenotypic trait for BD. 145 Affective tasks Studies incorporating affect-recognition tasks involve the presentation of verbal or visual material designed to stimulate emotions such as fear, sadness and happiness in subjects to explore the neural substrate of emotional dysregulation. A mixture of depressed and euthymic bipolar patients displayed increased subcortical and ventral prefrontal cortical responses to positive and negative facial emotional expressions, when compared with controls or unipolar depressed patients. 148 This response was largely uncorrelated with depression severity, and the authors interpreted their findings as supporting an increased responsiveness within neural systems important for emotion processing as characterizing BD.
Application of an emotional Stroop word task designed to implicitly induce affect identified diminished activation in subcortical and cortical regions, including the left ventral prefrontal cortex, in a sample of 12 euthymic patients compared with controls, 164 interpreted by the authors as indicative of a constrained ability of such patients to engage affective processing. A further fMRI study of an explicit facial emotional regulation task involving fear, disgust and neutral emotions identified hyperactivity in the hippocampus, inferior parietal and superior temporal cortices and the cerebellum among 10 female euthymic patients compared with matched controls, whereas patients had less activation in response to the disgust task including that in prefrontal regions. 165 An fMRI investigation of a word-based memory task designed to evoke affect in 10 euthymic bipolar patients compared with matched controls revealed a reduced activation in response to both positive and negative affect in several brain regions, including prefrontal, limbic, subcortical and cingulate areas, in the bipolar group. 166 Wessa et al. 149 used fMRI to examine the emotional modulation of cognitive processes in 17 euthymic patients and matched controls using emotional and non-emotional go/no-go tasks. Emotion-specific neural differences were detected as patients displayed overactivation in ventral-limbic, temporal and dorsal anterior and posterior cingulate regions during emotional go/no-go conditions, whereas no differences were observed when all go/no-go conditions were compared with the resting state. The authors interpreted their results as reflecting possible trait-related altered emotional modulation of cognitive processing in BD.
In summary, there has been an upsurge of functional neuroimaging studies of euthymic BD, assessing the resting state and a range of cognitive and affective paradigms. Despite the wide variety of tasks utilized, there is repeated evidence from these studies of abnormalities within key neural networks implicated in emotional regulation, including anterior limbic regions, ventral and dorsal prefrontal regions.
The studies generally include small numbers of participants and varying research methodologies and so the variable regional activations are unsurprising. However, several studies do identify increased activation in the emotional regulation brain areas incorporating subcortical, anterior limbic and temporal regions, in particular in response to tasks that involve emotional stimulation. On the other hand, studies mostly support attenuated cerebral activity in the more cognitive brain regions, including the dorsolateral prefrontal cortex and dorsal anterior cingulate. This research supports the existence of trait-based neural system abnormalities and is broadly consistent with a model by which there is inherently impaired cognitive control in association with increased responsiveness of brain regions involved in emotional regulation (Figure 2 ). This pattern of neural network abnormality then becomes accentuated during episodes of mood exacerbation. These studies press the case for further research to more clearly elucidate abnormalities in these neural networks, including replication in larger samples, examination of medication effects and longitudinal studies through different phases of illness. 167 
Conclusion and recommendations
This review has drawn together several strands of research in BD to highlight fundamental neurobiological trait abnormalities that may underpin this illness. Table 1 summarizes the trait abnormalities detectable at several levels of scale from intracellular molecular processes through to neural brain networks. These include elevated PKA activity, altered intracellular calcium signalling, enhanced pro-inflammatory cytokine production, glucocorticoid receptor dysfunction, reduced prefrontal NAA, white matter abnormalities and impaired functioning of anterior limbic and prefrontal neural networks.
There is insufficient evidence to integrate these diverse findings across various levels of scale into a definitive model of pathophysiology in BD; however, the findings do converge on trait neurobiological abnormalities within linked systems and neuroanatomical regions, which enables some inevitably speculative syntheses of the findings. For example, glucocorticoid excess and resistance, inflammatory activation and abnormal neurotrophic functioning could be linked to dendritic atrophy, reduced neuronal membrane synthesis, impaired neurogenesis and gliogenesis with subsequent volumetric deficits detectable on MR imaging.
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The hippocampus is particularly plastic and susceptible to the atrophic or neurotoxic effects of glucocorticoid excess, but such effects may be reversed by the neurotrophic effects of lithium, or of other mood stabilizers, on the medial temporal lobe. White matter abnormalities may disrupt key tracts and fuel the disturbed activation of neural networks underlying normal mood function. For example, if the long association fibres connecting key prefrontal and anterior limbic system networks were disrupted by white matter abnormalities, the removal of this prefrontal or cognitive inhibitory control could unleash increased cerebral activity within anterior limbic networks and the propensity to develop an abnormal mood state.
Despite the fact that inherent abnormalities appear to exist at many levels in BD, there are still considerable inconsistencies in the literature and it frequently remains unclear as to whether these abnormalities are causes or consequences of the illness or its treatment. Studies to date have tended to include relatively small numbers of patients and even euthymic/remitted samples can have substantial sources of clinical heterogeneity. These include the presence of subclinical manic or depressive symptoms, mixtures of diagnostic subtypes (bipolar I disorder, bipolar II disorder, rapid cycling illness, presence of psychotic symptoms), co-morbid substance or alcohol misuse and family history. Furthermore, many patients with euthymic BD continue to experience impaired occupational and social functioning. 168 One of the major limitations of the euthymic strategy is the extent of uncertainty to which changes are pharmacologically induced rather than trait based. Animal studies suggest that lithium and sodium valproate stimulate the extracellular signal-regulated kinase pathway, which may result in their anti-manic effect. 151 In addition, animal studies have shown that these two agents are associated with increased levels of neuroprotective proteins in the frontal cortex, 169 inhibition of apoptotic enzymes 146 and downregulation of synaptic expression of glutamate receptors in the hippocampus, 147 indicating a neuroprotective and neurotrophic role for these mood stabilizers in BD. 105 Neuroimaging studies reviewed above suggest a neurotrophic effect for lithium, and possibly also for valproate and quetiapine in BD. [104] [105] [106] [107] [108] [109] 111, 112, 152 The vast majority of the literature to date has been cross-sectional in nature. There is an inherent weakness in such studies as mood state, medication usage and disease progression most likely have dynamic and possibly interacting effects on many of the neurobiological indices reviewed in this paper. It is often impossible with such studies to determine whether neurobiological abnormalities, such as those of cellular functioning or neural network activation, are primary sources of pathophysiology or are compensatory mechanisms. Longitudinal studies bring the major advantage of powerful within-subject design and the possibility of teasing apart such dynamic and interacting effects.
Given the subtle alterations of neurobiological measures in BD, further cross-sectional studies of small heterogeneous samples are likely to provide only incremental advances in knowledge rather than secure any breakthroughs in the understanding of the aetiopathogenesis of BD. Future clinical investigations of these traits, which are likely to be most informative, will incorporate one or more of the following study designs: (i) purification of clinically homogenous patient subgroups, (ii) the assessment of medication-free patients, (iii) assessment of firstepisode manic patients, (iv) assessment of unaffected first-degree relatives or co-twins of patients, (v) assessment of the relationship between genotypic variation in putative susceptibility genes for BD and trait abnormalities, (vi) interinstitutional collaborative ventures to acquire complementary data on large numbers of patients and (vii) longitudinal studies across different phases of illness. Although methodologically challenging, in particular for multivariate data such as imaging, such longitudinal studies are feasible and some have been completed, for example assessing the effects of mood stabilizers on brain structure and the phosphoinositide system. We suggest that longitudinal studies should not sacrifice homogeneity for participant numbers but instead clinically homogenous cohorts of patients in a particular phase of illness, such as first-episode mania, euthymia and acute manic episode, should be reassessed during subsequent phases of illness through collaborative clinical research programmes.
Technological advances in recent years have enabled a range of investigative tools to be applied to samples of patients with BD, many of which are highlighted in this review. Combining these tools with rigorous clinical research methodology will help clarify the trait abnormalities underlying BD and dissect them from those that reflect mood state. The successful application of this approach will assist in a better understanding of the pathophysiology of the illness and facilitate the identification of those neurobiological abnormalities that represent intermediate phenotypes for genetic studies of BD and those that represent biological markers for examining the impact of treatment approaches.
